Bionano Genomics (BNGO) Receivables (2017 - 2026)

Bionano Genomics has disclosed Receivables across 10 years of filings, most recently posting $4.2 million for Q1 2026.

• Receivables for Q1 2026 came in at $4.2 million, up 23.76% year-over-year; the trailing twelve-month figure through Mar 2026 was $4.2 million (up 23.76% YoY), and the FY2025 annual result was $5.2 million, up 3.52% from the prior year.
• Receivables came in at $4.2 million for Q1 2026 at Bionano Genomics, down from $5.2 million in the prior quarter.
• In the past five years, Receivables ranged from a high of $9.7 million in Q4 2023 to a low of $3.4 million in Q1 2025.
• The 5-year median for Receivables is $6.0 million (2022), against an average of $6.1 million.
• Across the five-year window, Receivables surged 46.39% in 2022 and tumbled 59.65% in 2025, its largest moves.
• Bionano Genomics' Receivables stood at $7.5 million in 2022, then advanced by 28.88% to $9.7 million in 2023, then sank by 46.08% to $5.2 million in 2024, then climbed by 0.4% to $5.2 million in 2025, then decreased by 20.63% to $4.2 million in 2026.
• The last three Receivables figures came in at $4.2 million (Q1 2026), $5.2 million (Q4 2025), and $4.5 million (Q3 2025), per Business Quant data.